Effectiveness of Disease-Modifying Treatment on Spinal Cord Lesion Formation in Relapse-Onset Multiple Sclerosis: An MSBase Registry Study

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: Effectiveness of Disease-Modifying Treatment on Spinal Cord Lesion Formation in Relapse-Onset Multiple Sclerosis: An MSBase Registry Study ; volume:38 ; number:11 ; day:6 ; month:9 ; year:2024 ; pages:921-930 ; date:11.2024
CNS drugs ; 38, Heft 11 (6.9.2024), 921-930, 11.2024

Creator: Kreiter, Daniel
Kalincik, Tomas
Hupperts, Raymond
Patti, Francesco
Spitaleri, Daniele
Foschi, Matteo
Surcinelli, Andrea
Maimone, Davide
Yamout, Bassem
Khoury, Samia J.
Lechner-Scott, Jeannette
Ozakbas, Serkan
Gerlach, Oliver

Contributor: SpringerLink (Online service)

DOI: 10.1007/s40263-024-01115-x

URN: urn:nbn:de:101:1-2501062140584.156420025963

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 1:51 PM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Kreiter, Daniel
Kalincik, Tomas
Hupperts, Raymond
Patti, Francesco
Spitaleri, Daniele
Foschi, Matteo
Surcinelli, Andrea
Maimone, Davide
Yamout, Bassem
Khoury, Samia J.
Lechner-Scott, Jeannette
Ozakbas, Serkan
Gerlach, Oliver
SpringerLink (Online service)

Other Objects (12)

Current Disease-Modifying Therapies in Multiple Sclerosis

Disease-modifying treatments in Alzheimer’s disease

Disease-modifying effects of metabolic perturbations in ALS/FTLD

Lithium as a disease-modifying agent for prion diseases

Current experimental disease-modifying therapeutics for multiple system atrophy

Quality of life among injectable and oral disease-modifying therapy users in the Pacific Northwest Multiple Sclerosis Registry

Jellyfish mucin may have potential disease-modifying effects on osteoarthritis

Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy

Disease‐modifying effects of ganglioside GM1 in Huntington's disease models

Disease-modifying effects of ranibizumab for central retinal vein occlusion

Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis in the United States

Retrospective Claims Analysis of Treatment Patterns, Relapse, Utilization, and Cost Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy

Current Disease-Modifying Therapies in Multiple Sclerosis

Disease-modifying treatments in Alzheimer’s disease

Disease-modifying effects of metabolic perturbations in ALS/FTLD

Lithium as a disease-modifying agent for prion diseases

Current experimental disease-modifying therapeutics for multiple system atrophy

Quality of life among injectable and oral disease-modifying therapy users in the Pacific Northwest Multiple Sclerosis Registry

Jellyfish mucin may have potential disease-modifying effects on osteoarthritis

Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy

Disease‐modifying effects of ganglioside GM1 in Huntington's disease models

Disease-modifying effects of ranibizumab for central retinal vein occlusion

Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis in the United States

Retrospective Claims Analysis of Treatment Patterns, Relapse, Utilization, and Cost Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy

Current Disease-Modifying Therapies in Multiple Sclerosis

Disease-modifying treatments in Alzheimer’s disease

Disease-modifying effects of metabolic perturbations in ALS/FTLD

Lithium as a disease-modifying agent for prion diseases

Current experimental disease-modifying therapeutics for multiple system atrophy

Quality of life among injectable and oral disease-modifying therapy users in the Pacific Northwest Multiple Sclerosis Registry

Jellyfish mucin may have potential disease-modifying effects on osteoarthritis

Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy

Disease‐modifying effects of ganglioside GM1 in Huntington's disease models

Disease-modifying effects of ranibizumab for central retinal vein occlusion

Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis in the United States

Retrospective Claims Analysis of Treatment Patterns, Relapse, Utilization, and Cost Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Effectiveness of Disease-Modifying Treatment on Spinal Cord Lesion Formation in Relapse-Onset Multiple Sclerosis: An MSBase Registry Study

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Current Disease-Modifying Therapies in Multiple Sclerosis

Disease-modifying treatments in Alzheimer’s disease

Disease-modifying effects of metabolic perturbations in ALS/FTLD

Lithium as a disease-modifying agent for prion diseases

Current experimental disease-modifying therapeutics for multiple system atrophy

Quality of life among injectable and oral disease-modifying therapy users in the Pacific Northwest Multiple Sclerosis Registry

Jellyfish mucin may have potential disease-modifying effects on osteoarthritis

Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy

Disease‐modifying effects of ganglioside GM1 in Huntington's disease models

Disease-modifying effects of ranibizumab for central retinal vein occlusion

Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis in the United States

Retrospective Claims Analysis of Treatment Patterns, Relapse, Utilization, and Cost Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy

Current Disease-Modifying Therapies in Multiple Sclerosis

Disease-modifying treatments in Alzheimer’s disease

Disease-modifying effects of metabolic perturbations in ALS/FTLD

Lithium as a disease-modifying agent for prion diseases

Current experimental disease-modifying therapeutics for multiple system atrophy

Quality of life among injectable and oral disease-modifying therapy users in the Pacific Northwest Multiple Sclerosis Registry

Jellyfish mucin may have potential disease-modifying effects on osteoarthritis

Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy

Disease‐modifying effects of ganglioside GM1 in Huntington's disease models

Disease-modifying effects of ranibizumab for central retinal vein occlusion

Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis in the United States

Retrospective Claims Analysis of Treatment Patterns, Relapse, Utilization, and Cost Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy

Current Disease-Modifying Therapies in Multiple Sclerosis

Disease-modifying treatments in Alzheimer’s disease

Disease-modifying effects of metabolic perturbations in ALS/FTLD

Lithium as a disease-modifying agent for prion diseases

Current experimental disease-modifying therapeutics for multiple system atrophy

Quality of life among injectable and oral disease-modifying therapy users in the Pacific Northwest Multiple Sclerosis Registry

Jellyfish mucin may have potential disease-modifying effects on osteoarthritis

Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy

Disease‐modifying effects of ganglioside GM1 in Huntington's disease models

Disease-modifying effects of ranibizumab for central retinal vein occlusion

Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis in the United States

Retrospective Claims Analysis of Treatment Patterns, Relapse, Utilization, and Cost Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy

Related objects

Reset password